JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 243 filers reported holding JUNO THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $259,000 | -21.3% | 5,677 | -22.5% | 0.00% | 0.0% |
| Q3 2017 | $329,000 | -11.1% | 7,327 | -40.8% | 0.00% | -33.3% |
| Q2 2017 | $370,000 | -41.6% | 12,387 | -56.7% | 0.00% | -40.0% |
| Q1 2017 | $634,000 | +47.8% | 28,583 | +25.7% | 0.01% | +25.0% |
| Q4 2016 | $429,000 | -39.4% | 22,744 | -3.6% | 0.00% | -33.3% |
| Q3 2016 | $708,000 | +97.2% | 23,601 | +89.3% | 0.01% | +100.0% |
| Q2 2016 | $359,000 | +19.7% | 12,467 | +58.2% | 0.00% | 0.0% |
| Q1 2016 | $300,000 | +45.6% | 7,880 | +67.8% | 0.00% | +50.0% |
| Q4 2015 | $206,000 | -12.3% | 4,695 | -18.7% | 0.00% | 0.0% |
| Q3 2015 | $235,000 | – | 5,775 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 1,864,174 | $85,211,000 | 94.86% |
| Crestline Management, LP | 7,631,631 | $348,841,000 | 35.74% |
| Omega Fund Management, LLC | 753,564 | $34,445,000 | 24.90% |
| DDD Partners, LLC | 191,458 | $8,752,000 | 3.40% |
| SIB LLC | 100,000 | $4,571,000 | 3.28% |
| PECONIC PARTNERS LLC | 433,587 | $19,819,000 | 2.85% |
| Cormorant Asset Management, LP | 550,000 | $25,141,000 | 2.63% |
| ARK Investment Management | 682,495 | $31,197,000 | 2.48% |
| BB BIOTECH AG | 1,925,000 | $87,992,000 | 2.48% |
| Clarius Group, LLC | 120,988 | $5,530,000 | 2.47% |